Back to Search
Start Over
Dual anti-HER2 therapy (lapatinib and trastuzumab) plus capecitabine is a very effective and well-tolerated regimen (CLT) in metastatic HER2-positive breast cancer patients
- Publication Year :
- 2014
-
Abstract
- e11513 Background: Two targeted agents, trastuzumab and lapatinib, enhance apoptosis in Her2-positive breast cancer cells. After progression to trastuzumab, the combination of lapatinib and capecit...
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....1a226aea485c77ba3289c2de2aa30bf0
- Full Text :
- https://doi.org/10.13140/2.1.4977.1847